Novel SPR Chip Enhances Detection of High Refractive Index Biomarkers
Background
Surface Plasmon Resonance (SPR) is a widely used label-free optical sensing technique crucial for detecting molecular interactions in real-time, without the need for fluorescent tags. It's invaluable in drug discovery, environmental monitoring, and medical diagnostics. However, conventional SPR sensors often face limitations in accurately detecting samples with a high refractive index, which can include concentrated protein solutions or certain biological fluids, leading to reduced sensitivity and a narrow detection range. This study addresses this critical limitation by developing a multi working mode SPR chip specifically optimized for high refractive index detection.
Results
The newly developed multi working mode SPR chip demonstrated significantly enhanced performance, particularly for high refractive index samples. It achieved a remarkable 2.5-fold increase in sensitivity compared to traditional single-mode SPR sensors when detecting refractive index changes above 1.38. The detection limit for refractive index units (RIU) was improved by 43%, allowing for more precise measurements of subtle changes. Furthermore, the chip exhibited an extended dynamic range, capable of accurately monitoring samples with refractive indices up to 1.45, representing a 30% expansion over conventional designs. The novel multi working mode SPR chip demonstrated a remarkable 2.5-fold increase in sensitivity compared to conventional single-mode SPR sensors, particularly for samples with refractive indices above 1.38, opening new avenues for challenging biosensing applications. This enhanced performance was attributed to the optimized coupling efficiency and the ability to leverage multiple plasmonic resonances simultaneously, providing a more robust and responsive signal.
Why It Matters
This research represents a significant advancement in label-free biosensing technology, offering substantially improved capabilities for detecting high refractive index analytes. This could lead to more accurate and sensitive diagnostic tools for diseases where biomarkers are present in high concentrations or complex biological matrices. For instance, it could enable better detection of concentrated proteins in blood, urine, or other bodily fluids, potentially improving early disease detection and monitoring. The enhanced dynamic range also means a wider variety of samples can be analyzed without extensive dilution, streamlining research and clinical workflows. Future steps will involve validating this chip with complex clinical samples and potentially integrating it into portable diagnostic devices.